Managed Healthcare Executive June 24, 2024
Krazati is already available to treat patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
The FDA has granted accelerated approval to Krazati (adagrasib) in combination with cetuximab to treat adult patients with KRASG12C -mutated locally advanced or metastatic colorectal cancer (CRC).
Krazati was developed by Mirati Therapeutics, which is now a Bristol Myers Squibb company.
This is the second approved indication for Krazati. The FDA granted accelerated approval for Krazati in December 2022 to treat patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). It launched with wholesale acquisition cost for Krazati is $237,000 per year, or a monthly cost of $19,750 for 200 mg tablet/180 count bottle. Mirati offers a free...
Today's Sponsors
Today's Sponsor